Correspondingly, PD-L1 amplification has commonly been used as a positive predictive biomarker to blockade the PD-1/ PD-L1 axis in malignancies, including melanoma, NSCLC, and bladder cancer [4, 18, 19]. This evidence concerns the gene PDCD1 and melanoma.